Drug intelligence / Profile preview

SBL-001

Development stage: Preclinical
Lead developer: Sable Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

SBL-001 is a novel polycation nanomedicine being developed by Sable Therapeutics for the treatment of obesity. It is described as uniquely engineered for selective reduction of fat cell volume, representing a new molecular entity in the field of obesity therapies. The precise mechanism of action has not been publicly defined as of the latest available information. The drug originated from research at Columbia University and remains in early-stage development, with no clinical trials or regulatory approvals reported to date[2][3][9].

Beyond the preview

Go deeper on SBL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBL-001.

Explore the full profile